Image of Observatories section
In this section

OSFAR Publications

International publications


  • Otto M, Patrizio A, Jommi C, Variations in non-prescription drug consumption and expenditure: determinants and policy implications, Health Policy, published online February 3, 2018
  • Jommi C (2018). Managed Entry Agreements and High Cost Medicines (European Perspective), in Zaheer-Ud-Din Babar (ed.). Equitable Access to High-Cost Pharmaceuticals, Springer, London, 2018. Accepted for publication
  • Nayroles G, Frybourg S, Gabriel S, Kornfeld Å, Antoñanzas-Villar F, Espín J, Jommi C, et al (2017), Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. J Mark Access Health Policy; 5(1):1298190.
  • Toumi M, Zard J, Abdallah IB, Jommi C, Cohen J (2017). An overview of Market Access Agreements. in Ethgen O, Staginnus O (ed), The future of Health Economics. Routledge, 75-108.
  • Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E, Gerkens S, Henschke C, Hislop J, Jommi C, et al. (2016), Pharmaceutical regulation in 15 European countries review. Health Syst Transit;18(5):1-122.
  • Armeni P, Jommi C, Otto M. (2016), The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study, Eur J Health Econ;17(8):963-977.
  • Jommi C. (2015), Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries. Global&Regional HTA;2(3):117-162.
  • Jommi C, Minghetti P (2015). Pharmaceutical Pricing Policies in Italy, in (Zaheer-Ud-Din Babar (ed.), Pharmaceutical Prices in the 21st Century, Springer, London, pp. 131-151
  • Jommi C, Dellamano L (2013), Valutazione del beneficio incrementale e prezzo di cessione per i farmaci rimborsati: il caso dell'AMNOG tedesco. PharmacoEconomics Italian Research Articles;15(Suppl.):25-33.              
  • Jommi C, Costa E, Michelon A, et al. (2013), Multi-tier drugs assessment in a decentralised health care system. The Italian case-study, Health Policy; 112(3):241-247.
  • Ghislandi S, Armeni P, Jommi C. (2013), The impact of generic reference pricing in Italy, a decade on. Eur J Health Econ.14(6), 959-69

 

National publications


  • Armeni P, Bertolani A, Costa F, Jommi C, Otto M (2017), Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, in AAVV (a cura di), Rapporto OASI 2017, Egea, Milano.
  • Jommi C, Costa F. (2013), I prezzi a ricavo industria dei farmaci rimborsabili: l’Italia a confronto con i principali paesi Ue, Politiche Sanitarie;14(2):1-12.
  • Jommi C, Armeni P, De Luca C, Otto M, Vella V (2012). Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa, Cantù E (a cura di), Rapporto OASI 2011, Egea, Milano.
  • Jommi C, Armeni P, De Luca C, et al (2012), Market access management by pharmaceutical companies in a complex environment. The Italian case-study, Journal of Medical Marketing, 12-2, 93-103.
  • Jommi C (2011). Value Based Pricing per i farmaci, in De Vincenti C., Finocchi Ghersi, A., Tardiola, A., La Sanità in Italia, Organizzazione, governo, regolazione, mercato. Il Mulino, Bologna.
  • Compagni A, Cavalli L, Jommi C (2008), Pharmaceutical companies and Italian Regional Governments: Managing relationships in an increasing institutional complexity. Health Policy 87 333–341.
  • Fattore G., Jommi C. (2008), “The last decade of Italian Pharmaceutical Policy: Instability or Consolidation?, Pharmacoeconomics, 26, 5-15.
  • Jommi C., Paruzzolo (2007), “Public administration and R&D localisation by pharmaceutical and biotech companies: a theoretical framework and the Italian case study”, Health Policy, 81, 117-130.